George Scangos

2021

In 2021, George Scangos earned a total compensation of $20.7M as President and Chief Executive Officer at Vir Biotechnology, a 1,979% increase compared to previous year.

Compensation breakdown

Non-Equity Incentive Plan$487,000
Option Awards$12,129,858
Salary$575,000
Stock Awards$7,479,180
Other$11,600
Total$20,682,838

Scangos received $12.1M in option awards, accounting for 59% of the total pay in 2021.

Scangos also received $487K in non-equity incentive plan, $575K in salary, $7.5M in stock awards and $11.6K in other compensation.

Rankings

In 2021, George Scangos' compensation ranked 305th out of 12,415 executives tracked by ExecPay. In other words, Scangos earned more than 97.5% of executives.

ClassificationRankingPercentile
All
305
out of 12,415
98th
Division
Manufacturing
92
out of 5,505
98th
Major group
Chemicals And Allied Products
28
out of 2,375
99th
Industry group
Drugs
24
out of 2,096
99th
Industry
Biological Products, Except Diagnostic Substances
11
out of 449
98th
Source: SEC filing on April 7, 2022.

Scangos' colleagues

We found four more compensation records of executives who worked with George Scangos at Vir Biotechnology in 2021.

2021

Phillip Pang

Vir Biotechnology

Chief Medical Officer

2021

Herbert Virgin

Vir Biotechnology

Chief Scientific Officer

2021

Howard Horn

Vir Biotechnology

Chief Financial Officer

2021

Ann Hanly

Vir Biotechnology

Chief Technology Officer

News

In-depth

You may also like